iRhythm Technologies (IRTC) Competitors

iRhythm Technologies logo
$90.83 -1.08 (-1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$90.78 -0.05 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IRTC vs. GKOS, PEN, SNN, BAX, and GMED

Should you buy iRhythm Technologies stock or one of its competitors? iRhythm Technologies's main competitors and comparable companies include Glaukos (GKOS), Penumbra (PEN), Smith & Nephew SNATS (SNN), Baxter International (BAX), and Globus Medical (GMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does iRhythm Technologies compare to Glaukos?

Glaukos (NYSE:GKOS) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, iRhythm Technologies had 17 more articles in the media than Glaukos. MarketBeat recorded 20 mentions for iRhythm Technologies and 3 mentions for Glaukos. Glaukos' average media sentiment score of 0.88 beat iRhythm Technologies' score of 0.20 indicating that Glaukos is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Glaukos
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iRhythm Technologies
2 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Glaukos presently has a consensus target price of $216.71, suggesting a potential downside of 11.76%. iRhythm Technologies has a consensus target price of $164.07, suggesting a potential upside of 78.51%. Given iRhythm Technologies' higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than Glaukos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

iRhythm Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$507.44M28.65-$187.69M-$2.94N/A
iRhythm Technologies$747.14M4.14-$44.55M-$1.17N/A

99.0% of Glaukos shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

iRhythm Technologies has a net margin of -4.52% compared to Glaukos' net margin of -24.60%. iRhythm Technologies' return on equity of 26.88% beat Glaukos' return on equity.

Company Net Margins Return on Equity Return on Assets
Glaukos-24.60% -0.97% -0.71%
iRhythm Technologies -4.52%26.88%4.32%

Glaukos has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Summary

iRhythm Technologies beats Glaukos on 9 of the 14 factors compared between the two stocks.

How does iRhythm Technologies compare to Penumbra?

Penumbra (NYSE:PEN) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Penumbra has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.40B9.01$177.69M$3.9780.85
iRhythm Technologies$747.14M4.14-$44.55M-$1.17N/A

In the previous week, iRhythm Technologies had 20 more articles in the media than Penumbra. MarketBeat recorded 20 mentions for iRhythm Technologies and 0 mentions for Penumbra. iRhythm Technologies' average media sentiment score of 0.20 beat Penumbra's score of 0.13 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Penumbra Neutral
iRhythm Technologies Neutral

Penumbra has a net margin of 10.06% compared to iRhythm Technologies' net margin of -4.52%. iRhythm Technologies' return on equity of 26.88% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra10.06% 10.39% 8.09%
iRhythm Technologies -4.52%26.88%4.32%

Penumbra has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Penumbra currently has a consensus price target of $367.07, indicating a potential upside of 14.37%. iRhythm Technologies has a consensus price target of $164.07, indicating a potential upside of 78.51%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

88.9% of Penumbra shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Penumbra beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does iRhythm Technologies compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Smith & Nephew SNATS has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

In the previous week, iRhythm Technologies had 15 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 20 mentions for iRhythm Technologies and 5 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 0.47 beat iRhythm Technologies' score of 0.20 indicating that Smith & Nephew SNATS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew SNATS
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
iRhythm Technologies
2 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Smith & Nephew SNATS currently has a consensus target price of $31.91, suggesting a potential upside of 2.16%. iRhythm Technologies has a consensus target price of $164.07, suggesting a potential upside of 78.51%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

Smith & Nephew SNATS has higher revenue and earnings than iRhythm Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew SNATS$6.30B2.08$625MN/AN/A
iRhythm Technologies$747.14M4.14-$44.55M-$1.17N/A

Smith & Nephew SNATS has a net margin of 0.00% compared to iRhythm Technologies' net margin of -4.52%. iRhythm Technologies' return on equity of 26.88% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew SNATSN/A N/A N/A
iRhythm Technologies -4.52%26.88%4.32%

Summary

iRhythm Technologies beats Smith & Nephew SNATS on 9 of the 15 factors compared between the two stocks.

How does iRhythm Technologies compare to Baxter International?

iRhythm Technologies (NASDAQ:IRTC) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

iRhythm Technologies has a net margin of -4.52% compared to Baxter International's net margin of -6.23%. iRhythm Technologies' return on equity of 26.88% beat Baxter International's return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-4.52% 26.88% 4.32%
Baxter International -6.23%16.23%5.08%

90.2% of Baxter International shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iRhythm Technologies currently has a consensus target price of $164.07, indicating a potential upside of 78.51%. Baxter International has a consensus target price of $23.27, indicating a potential downside of 9.69%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe iRhythm Technologies is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82
Baxter International
3 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86

In the previous week, iRhythm Technologies had 12 more articles in the media than Baxter International. MarketBeat recorded 20 mentions for iRhythm Technologies and 8 mentions for Baxter International. Baxter International's average media sentiment score of 0.83 beat iRhythm Technologies' score of 0.20 indicating that Baxter International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
2 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Baxter International
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

iRhythm Technologies has higher earnings, but lower revenue than Baxter International. iRhythm Technologies is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$747.14M4.14-$44.55M-$1.17N/A
Baxter International$11.24B1.19-$957M-$1.41N/A

iRhythm Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Baxter International has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Summary

iRhythm Technologies beats Baxter International on 12 of the 17 factors compared between the two stocks.

How does iRhythm Technologies compare to Globus Medical?

iRhythm Technologies (NASDAQ:IRTC) and Globus Medical (NYSE:GMED) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

iRhythm Technologies presently has a consensus price target of $164.07, indicating a potential upside of 78.51%. Globus Medical has a consensus price target of $96.08, indicating a potential upside of 33.42%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe iRhythm Technologies is more favorable than Globus Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82
Globus Medical
0 Sell rating(s)
7 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.63

Globus Medical has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$747.14M4.14-$44.55M-$1.17N/A
Globus Medical$2.94B3.25$537.87M$4.0717.69

Globus Medical has a net margin of 17.76% compared to iRhythm Technologies' net margin of -4.52%. iRhythm Technologies' return on equity of 26.88% beat Globus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
iRhythm Technologies-4.52% 26.88% 4.32%
Globus Medical 17.76%14.43%12.52%

95.2% of Globus Medical shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

iRhythm Technologies has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, iRhythm Technologies had 4 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for iRhythm Technologies and 16 mentions for Globus Medical. iRhythm Technologies' average media sentiment score of 0.20 beat Globus Medical's score of 0.14 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
2 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Globus Medical
5 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

iRhythm Technologies and Globus Medical tied by winning 8 of the 16 factors compared between the two stocks.

Get iRhythm Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRTC vs. The Competition

MetriciRhythm TechnologiesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.15B$5.97B$7.83B$11.75B
Dividend YieldN/A1.68%2.47%4.41%
P/E Ratio69.8239.0934.3430.11
Price / Sales4.094.848.005.34
Price / CashN/A24.1821.0222.34
Price / Book17.244.954.763.85
Net Income-$44.55M$143.12M$3.52B$393.14M
7 Day Performance2.37%-4.86%-5.34%-4.53%
1 Month Performance-16.41%-2.87%-3.61%-5.86%
1 Year Performance-46.83%-0.76%0.01%-7.78%

iRhythm Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRTC
iRhythm Technologies
3.5342 of 5 stars
$90.83
-1.2%
$164.07
+80.6%
-46.2%$3.15B$747.14M69.822,400
GKOS
Glaukos
2.6315 of 5 stars
$223.96
+1.8%
$216.71
-3.2%
+172.7%$14.12B$507.44MN/A1,094
PEN
Penumbra
1.7088 of 5 stars
$319.35
-0.5%
$367.07
+14.9%
+14.5%$12.67B$1.40B81.354,700
SNN
Smith & Nephew SNATS
1.7102 of 5 stars
$31.16
-2.7%
$31.91
+2.4%
-4.5%$12.66B$6.16BN/A16,988
BAX
Baxter International
2.3752 of 5 stars
$25.74
+0.3%
$23.00
-10.6%
+39.6%$12.53B$11.24B12.4837,500

Related Companies and Tools


This page (NASDAQ:IRTC) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners